Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself

CM McCrudden, MG O'Rourke, KE Cherry, HF Yuen, D O'Rourke, M Babur, BA Telfer, HD Thomas, P Keane, T Nambirajan, C Hagan, JM O'Sullivan, C Shaw, KJ Williams, NJ Curtin, DG Hirst, T Robson

    Research output: Contribution to journalArticlepeer-review

    Original languageEnglish
    Article numbere0118187
    Pages (from-to)e0118187
    JournalP L o S One
    Issue number2
    Publication statusPublished - 17 Feb 2015

    Cite this